Cinda Bio and Roche work closely to discover and develop multiple cell therapies and bispecific antibody products

Read: Cinda Bio and Roche Group reach a potential $2 billion strategic partnershiptoday announced that it has entered into a strategic research and development partnership with Roche to identify and develop multiple products, including tumor cell therapy and bispecific antibodiescollaboration will focus on research, clinical development and commercialization of multiple bispecific antibody and cell therapy products that will be used directly in blood and solid tumor therapyunder the terms of the partnership, Cinda Bio will pay a down payment, development and commercial milestones and product sales commission for its use of Roche's technology developed 2:1 dual-specific T-cell antibodies and generic CAR-T platformsCinda Bio will be responsible for product development, production and commercializationRoche reserves the exclusive repurchase option for the development and commercialization of these products outside ChinaIf Roche exercises all of its options, it will pay Cinda Bio a total of $140 million and, if all products are successfully developed and commercialized, pay a milestone of approximately $1.96 billion for product development, approval and sale, in addition to a double-digit sales increase for each product